Home » All the Latest News » Research and Research Round Up » Media Coverage of early trials of new medicine to treat Epilepsy in Tuberous Sclerosis

Media Coverage of early trials of new medicine to treat Epilepsy in Tuberous Sclerosis

The academic journal, Annals of Neurology, has recently accepted a paper by researchers at Texas Children’s Hospital, Baylor College of Medicine and Cincinnati Children’s Hospital. This small study shows promising results in a small number of TSC patients being treated with Everolimus for Epilepsy. This paper has resulted in some very positive media coverage.

Link to the study

Krueger, D.A., et al., Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Annals of Neurology, 2013

You can read the abstract of the article here: https://onlinelibrary.wiley.com/doi/10.1002/ana.23960/abstract

Media Coverage

You can read some of the articles written about this study here:





The following promotional video has been produced by Texas Children’s Hospital:

“We believe this is the first step on a long pathway of completely changing our ability to manage many different types of epilepsy. This is completely a game changer” Dr Angus Wilfong, Medical Director, Comprehensive Epilepsy Program, Texas Children’s Hospital

What does this study mean to TSC affected families in Australia and New Zealand?

This study only included 20 patients and did not include a comparrison group, that is, all 20 patients were treated with Everolimus. The next step is a larger, worldwide clinical trial that is already being planned. This study will include several sites in Australasia. If this larger study shows positive results, this new medicine may be approved in the future to treat Epilepsy associated with Tuberous Sclerosis in Australia and New Zealand.

You can read more about the larger study at https://www.clinicaltrials.gov/ct2/show/NCT01713946

If you have any questions about how this information may apply to your individual circumstance, you should discuss this with your own doctor.

Leave a Reply